HIV,highly active antiretroviral therapy and the heart: a cellular to epidemiological review |
| |
| Authors: | CT Lambert PB Sandesara B Hirsh LJ Shaw W Lewis AA Quyyumi RF Schinazi WS Post L Sperling |
| |
| Affiliation: | 1. Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA;2. Division of Cardiology, Department of Medicine, Mt Sinai School of Medicine, New York, NY, USA;3. Department of Pathology, Emory University School of Medicine, Atlanta, GA, USA;4. Department of Pediatrics, Center for AIDS Research, Emory University School of Medicine, Atlanta, GA, USA;5. Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA |
| |
| Abstract: | The advent of potent highly active antiretroviral therapy (HAART) for persons infected with HIV‐1 has led to a “new” chronic disease with complications including cardiovascular disease (CVD). CVD is a significant cause of morbidity and mortality in persons with HIV infection. In addition to traditional risk factors such as smoking, hypertension, insulin resistance and dyslipidaemia, infection with HIV is an independent risk factor for CVD. This review summarizes: (1) the vascular and nonvascular cardiac manifestations of HIV infection; (2) cardiometabolic effects of HAART; (3) atherosclerotic cardiovascular disease (ASCVD) risk assessment, prevention and treatment in persons with HIV‐1 infection. |
| |
| Keywords: | atherosclerotic cardiovascular disease cardiovascular disease endothelial dysfunction highly active antiretroviral therapy
HIV
prevention |
|
|
